Denali Therapeutics (NASDAQ:DNLI) Sets New 12-Month Low at $38.51

Denali Therapeutics Inc. (NASDAQ:DNLI)’s share price reached a new 52-week low on Thursday . The company traded as low as $38.51 and last traded at $38.55, with a volume of 527741 shares traded. The stock had previously closed at $41.74.

A number of research firms have recently weighed in on DNLI. Oppenheimer began coverage on Denali Therapeutics in a research report on Monday, September 20th. They issued an “outperform” rating and a $85.00 price objective for the company. Zacks Investment Research raised Denali Therapeutics from a “sell” rating to a “hold” rating and set a $49.00 price objective for the company in a research report on Friday, November 19th. Evercore ISI raised their price objective on Denali Therapeutics from $70.00 to $111.00 and gave the stock an “outperform” rating in a research report on Friday, November 5th. Finally, Morgan Stanley lowered their price target on Denali Therapeutics from $99.00 to $91.00 and set an “overweight” rating for the company in a research report on Thursday, January 6th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $86.75.

The stock has a 50-day simple moving average of $45.53 and a 200 day simple moving average of $51.62. The company has a market cap of $4.25 billion, a price-to-earnings ratio of 248.87 and a beta of 1.75.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Thursday, November 4th. The company reported ($0.69) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.23). The company had revenue of $5.29 million for the quarter, compared to analysts’ expectations of $30.28 million. Denali Therapeutics had a net margin of 8.38% and a return on equity of 2.72%. The business’s quarterly revenue was down 43.7% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.54) EPS. On average, research analysts forecast that Denali Therapeutics Inc. will post -2.2 earnings per share for the current fiscal year.

In related news, Director Marc Tessier-Lavigne sold 20,047 shares of Denali Therapeutics stock in a transaction dated Thursday, December 30th. The stock was sold at an average price of $45.36, for a total value of $909,331.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Carole Ho sold 1,476 shares of Denali Therapeutics stock in a transaction dated Monday, December 6th. The shares were sold at an average price of $42.52, for a total value of $62,759.52. The disclosure for this sale can be found here. Insiders have sold a total of 85,425 shares of company stock valued at $3,900,471 in the last quarter. Company insiders own 17.00% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Itau Unibanco Holding S.A. purchased a new position in shares of Denali Therapeutics in the 2nd quarter valued at about $29,000. Dark Forest Capital Management LP increased its stake in shares of Denali Therapeutics by 19,733.3% in the 3rd quarter. Dark Forest Capital Management LP now owns 595 shares of the company’s stock valued at $30,000 after purchasing an additional 592 shares in the last quarter. Patriot Financial Group Insurance Agency LLC increased its stake in shares of Denali Therapeutics by 125.3% in the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 811 shares of the company’s stock valued at $36,000 after purchasing an additional 451 shares in the last quarter. Point72 Hong Kong Ltd purchased a new stake in Denali Therapeutics during the 3rd quarter worth approximately $45,000. Finally, PNC Financial Services Group Inc. increased its stake in Denali Therapeutics by 30.4% during the 3rd quarter. PNC Financial Services Group Inc. now owns 1,211 shares of the company’s stock worth $61,000 after buying an additional 282 shares in the last quarter. Hedge funds and other institutional investors own 68.84% of the company’s stock.

Denali Therapeutics Company Profile (NASDAQ:DNLI)

Denali Therapeutics, Inc is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

See Also: Fiduciary

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.